Peran Lumbrokinase pada Tata Laksana Stroke Iskemik


  • Marcellinus Michael Leonard Mardiono RS Gading Pluit



Cardiovascular, lumbrokinase, stroke


Stroke is a major cause of disability and cognitive impairment, accounting for 5.2% deaths worldwide. Antiplatelets and anticoagulants have been widely used as prevention of recurrent stroke. Recently, lumbrokinase has been used in stroke and other cardiovascular patients, but further research is needed.


Download data is not yet available.


Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation. 2017;135:e146–e603.

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459–1544.

Wijaya HR, Supriyanto E, Salim MI, Eryando T. Stroke management cost: Review in Indonesia, Malaysia and Singapore. AIP Conf Proc. 2019;2092(1):030022

Prayitno L, Sugiharto M, Pratiwi NL. Ischemic Stroke Caused by Metabolic Factors in Indonesia ( GBD Study 2017). Indian J Forensic Med Toxicol 2020;14: 3082-9

Prasad M, Marandi S, Mishra B, Guria RT, Kumar A,Birua H, Ray HN, Dungdung A, Kumar D, Maitra S. Association of fibrinogen with ischemic stroke : A systematic review and meta analysis. Cureus 2023 Jan; 15(1): e34335.

Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis 2009;27:493–501

Uchino K, Pary J, Grotta J. Acute Stroke Care, 2nd ed, New York: Cambridge University Press. 2011.

Bailey EL, Smith C, Sudlow CL, Wardlaw JM. Pathology of lacunar ischemic stroke in humans-a systematic review. Brain Pathol. 2012;22:583–91.

Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211–24

Hsieh FI, Chiou HY. Stroke: Morbidity, risk factors, and care in Taiwan. J Stroke. 2014;16(2):59-64.

Lin H.-J, Wolf PA, Kelly-Hayes M, Beiser A, Kase CS, Benjamin EJ, D’Agostino SRB. Stroke severity in atrial fibrillation. Stroke. 1996;27:1760–4

Ramos-Cabrer P, Campos F, Sobrino T, Castillo J. Targeting the ischemic penumbra. Stroke 2011;42:S7–11

Paul S, Jalil EC. Emerging neuroprotective studies for the treatment of ischemic stroke: an overview of clinical and preclinical studies. PubMed Central 2020. DOI: 10.1016/j.expneurol.2020.113518

Maida CD, Norrito RL, Daidone M., Tottulomondo A., Pinto A. Neuroinflammatory mechanisms in ischemic stroke: Focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci. 2020;21(18):6454.

Han W, Pu H, Li S, Liu Y, Zhao Y, Xu M, et al. Targeted ablation of signal transducer and activator transducer 1 alleviates inflammation by microglia/macrophages and promote long-term recovery after ischemic stroke. J Neuroinflammation. 2023;20:178

Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long -term risk of recurrent stroke after a first-ever stroke. Stroke 1994;25:333-7

Tao T, Liu M, Chen M, Luo Y, Wang C, Xu T, et al. Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective. Pharmacol Therapeut. 2020;216:1-24

Wang HS, Liao JM, Chen KM, Su HH, Liu PH, Chen YH, Tsuei YS, Tsai CF, Huang SS. Lumbrokinase regulates endoplasmic reticulum stress to improve neurological deficits in ischemic stroke. Neuropharmacology.2022;221

Becker DE. Antithrombotic drugs: Pharmacology and implications for dental practice. Anesthesia Progr. 2013; 60(2): 72–80.

Cao YJ, Zhang X, Wang WH, Zhai WQ, Qian JF, Wang JS, et al. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: Results from a multicenter, randomized, parallel-group and controlled clinical trial. Chinese Med J. .2013;126(21):4060–5,

Simangungsong M, Bihantoro, Wijayanti Z, Aisyah E, Mustikawati N, Tjandrawinata R, et al. Role of DLBS1033 in the management of acute ischemic stroke patients: Study protocol for a randomized controlled study. Chin Med J. 2023;126(21):4060-5. DOI: 10.4103/2468-5577.181235.

Mihar H, Sumi H, Yoneta T, Mizumoto H, Ikeda R, Seiki M, et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol. 1991; 41(3):461–72.

Sukmawan YP. Lumbrokinase reduced the fibrinogen concentration in ischemic cerebrovascular disease patients: A systematic review and metaanalysis. Indon J Clin Pharm. 2020;9(1):43.

Pinzon RT, Tjandrawinata R, Wijaya VO, Veronica V. Effect of DLBS1033 on functional outcomes for patients with ischemic stroke: A randomized controlled trial. Stroke Res Treatment 2021;2021:1-9.

You S, Zhong C, Mao X, Ou Z, Wang L, Xu J, et al. Efficacy and safety of lumbrokinase capsule for acute ischemic stroke: A meta-analysis [in Chinese] China J Evid-based Med. 2020;20(07):829–36.

Setyopranoto I, Wibowo S, Tjandrawinata R. Hemostasis profile and clinical outcome of acute ischemic stroke patients treated with oral lumbrokinase DLBS1033: A comparative study versus aspirin and clopidogrel. Asian J Pharmaceut Clin Res. 2016;9: 171-7.

Zuo Y. Effect of lumbrokinase combined with aspirin in secondary prevention of cerebral infarction [in Chinese] Chin J Pract Nerv Dis. 2015;18(01):119–20.



How to Cite

Mardiono, M. M. L. (2024). Peran Lumbrokinase pada Tata Laksana Stroke Iskemik. Cermin Dunia Kedokteran, 51(2), 95–98.